GSK at a glance

Who we are

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of more than 2.5 billion individuals by 2031, with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

What we do

We prevent and treat disease with vaccines, specialty and general medicines.

In 2023:

£30.3bn medicines and vaccine sales
71 vaccines and medicines in development
£6.2bn R&D investment
10 products exceeding 1bn sales

We focus on science of the immune system and advanced technologies, investing in 4 core therapeutic areas (Infectious Diseases, HIV, Respiratory/Immunology and Oncology) to impact health at scale.

We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.

Our portfolio:

Vaccines
Our broad vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from meningitis, shingles, RSV, flu, polio and many more.

Specialty Medicines
We continue to be global leaders in infectious diseases, respiratory and HIV medicines and have an emerging portfolio of cancer medicines.

General Medicines
From antibiotics to inhaled medicines for asthma and COPD, we have over 150 general medicine products, many of them leaders in their class, making life better for millions of people worldwide.
Our priorities

Innovation
We believe the powerful combination of disruptive science and advanced data and platform technologies is transforming medical discovery, enabling us to find new ways to prevent and treat the most challenging diseases, better and faster.

Performance
New upgraded growth commitments to 2026 and over £38bn in sales by 2031.
Our bold ambitions mean more GSK vaccines and medicines than ever before, including innovative new products, reaching people who need them.

Trust
Delivering our strategy responsibly: always considering the social, environmental and governance impacts of everything we do from lab to patient.
We’re taking action in six areas that matter most to us: access to medicines; global health and health security; diversity, equity and inclusion; environment; product governance and ethical standards.

In 2023:

18 pipeline assets in phase III/registration
6 major business development deals
£30.3bn medicines and vaccine sales
2.3bn packs of medicines and vaccine doses delivered
1st in the Access to Medicine Index
1st Sector leaders of the S&P’s Global Corporate Sustainability Assessment

Our culture
We have over 70,000 people in more than 75 countries worldwide and culture at GSK is something we all own.

We are ambitious for patients to deliver what matters better and faster.

We are accountable for impact with clear ownership and support to succeed.

We do the right thing with integrity and care because people count on us.

This powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive.

These are the foundations for how, together, we’ll deliver more for our patients, shareholders and GSK people.

Why we do it
We aim to get ahead of disease together – to positively impact the health of 2.5 billion people by 2031.